Interesting insights into phase I trial recruitment in oncology and health care utilization using data extracted from unstructured text in health care records. pubmed.ncbi.nlm.nih.gov/40855012/ @icr.ac.uk @royalmarsden.org @ecmc-uk.bsky.social @crukconvergence.bsky.social @nihr.bsky.social

Organoid culture is prohibitively expensive. Solution to Harvest Organoids Efficiently (SHOE) allows rapid and inexpensive harvesting of organoids. Please use in your research labs and cite. pubmed.ncbi.nlm.nih.gov/40641211/ @icr.ac.uk @royalmarsden.org @crukconvergence.bsky.social

Antibody-drug-conjugate toxicity is real and poorly understood. Looking for trends in association with antibody/linker/payloads. pubmed.ncbi.nlm.nih.gov/40611310/ @icr.ac.uk @royalmarsden.org @ecmc-uk.bsky.social @crukconvergence.bsky.social

Published today @natmed.nature.com www.nature.com/articles/s41...
Thank you to all patients, families and research staff. @icr.ac.uk @icrdduiit.bsky.social‬ ‪@icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social‬
@nihr.bsky.social @crukconvergence.bsky.social @cancerresearchuk.org

‪

Published today in @natmed.nature.com www.nature.com/articles/s41... combination of avutometinib and defactinib in LGSOC. @icr.ac.uk‬ @icrdduiit.bsky.social‬ @icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social
@nihr.bsky.social‬ ‪@crukconvergence.bsky.social @cancerresearchuk.org

‪

#MCCR2025. Methods in clinical cancer research workshop hits its 25 year birthday! Fabulous opportunity to train young oncologists to develop research protocols. Especially proud to have been a trainee over 20 years ago and having served as faculty. @ESMO @EORTC @theaacr.bsky.social

Sharing good practice to run complex radio-immuno conjugate trials in the UK to accelerate drug development and improve outcomes of cancer patients. @ecmc.bsky.social @icr.ac.uk @icrdduiit.bsky.social @nihr.bsky.social @cruk.bsky.social

Professor Paul Workman, fellow of AACR, talking on the urgency in developing chemical probes to fight cancer. #AACR2025 @icr.ac.uk

End of a long day at AACR. Presented using patient derived organoids to understand and refine mechanisms of synergy of avutometinib and defactinb combination in low grade ovarian, an area of unmet need. @icr.ac.uk @crukconvergence.bsky.social @nihr.bsky.social @ecmc-uk.bsky.social

Love the art 🎨, only advice, make sure you patent anything important before you publish (on your sleeve)!! 🙂 #AACR2025

Masterclass in next generation ADCs! ED11 #AACR2025 worth watching online if you missed it.

Only at #AACR 2025, Love the commitment!!!

#AACR2025 has begun. Educational sessions on plasticity/drug resistance and models of cancer evolution. Feel the buzz! @icr.ac.uk @cancerresearchuk.org @nihr.bsky.social

Happy retirement to my wife Jane, joined nurse training 42 years ago, worked across several NHS trusts and Australian public hospitals on clinical trials of carboplatin, VP16 (etoposide), GCSF, ondansetron and CHART RT in clinic. Worked in tral management @icr since 2005. Time to put up your feet!

www.icr.ac.uk/about-us/icr... Blog about projects @icrlondon.bsky.social in ovarian cancer. Its only the tip of the iceberg, there are many exciting projects too early to talk about! Blessed to be a small cog in the big wheel of progress in cancer research at my institution and beyond…

Unfolded protein response meets AR transcription. We need to think out the box to tackle known oncogenic drivers. Great piece of work from my colleague @AdamSharpMedOnc out this week aacrjournals.org/clincancerre... @icrlondon.bsky.social @theaacr.bsky.social

Very interesting personalized m-RNA cancer vaccine paper in nature medicine www.nature.com/articles/s41... published this week establishing proof concept of the technology. Trial was led by my colleague Juantia Lopez and our unit was involved as part of an international clinical trial.